"The experimental drug daraxonrasib targets 'undruggable' RAS proteins. Trial participants with advanced pancreatic cancer lived 13.2 months on average, compared to 6.7 months with chemotherapy. Researchers suggest potential for longer-lasting benefits when combined with other treatments."